RARE - DOJ says Ultragenyx to pay $6M to resolve Medicare claims allegations
2023-12-21 17:57:17 ET
More on Ultragenyx Pharmaceutical
- Ultragenyx: Speculative Innovation Amidst High Expenditures Merits Caution (Rating Downgrade)
- Ultragenyx Pharmaceutical, Inc. (RARE) Q3 2023 Earnings Call Transcript
- Ultragenyx Pharmaceutical Inc. 2023 Q3 - Results - Earnings Call Presentation
- Wells Fargo starts Ultragenyx coverage with overweight rating
- Ultragenyx Pharmaceutical GAAP EPS of -$2.23 misses by $0.12, revenue of $98.1M misses by $4.78M
For further details see:
DOJ says Ultragenyx to pay $6M to resolve Medicare claims allegations